Opinions
David Fingold
Hoya Corporation
7741-JP
TOP PICK
Apr 07, 2020
Price target: 10,237 Yen The second-biggest maker of eyeglass lenses and a low-cost producer. He expects Hoya to take market share. It's also the world's second-biggest maker of endoscopes which will be used in selective procedures return post-lockdown. Hoya has been doing well, given its monopoly in photomasks used in lithography. Also are the only producer of glass used in hard-disk platters which helps transfer more data in a hard disc, which are seeing high demand.
N/A
Stock price when the opinion was issued
Healthcare
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
TOP PICK
The price target is in Japanese yen. Expertise is in glass. There is pent-up demand in eye glasses. They are number 2 in the world. They are also a producer of a substrate for hard disk platters. They also dominate the photo lithography for semiconductors. A play on the extreme ultraviolet lithography. (Analysts’ price target is $16600.00)
Healthcare
COMMENT
Second largest producer of eye glasses and other glass products such as endoscopes, etc. Very high quality company with strong margins and long term record of growth. There is growth opportunity in eye glasses. Endoscope area could present a challenge with possible switch to disposable technology. Stewards of capital eg. dividend growth. An entrepreneurial company, one of the best in Japan.
Healthcare
BUY ON WEAKNESS
Very good longer term. Reasonable balance sheet. Shareholder support is quite good. Reasonable returns. Beneficiary of semiconductor business. With volatility, stock probably moves further south, so chance to pick it up lower. Be aware that Japan's central bank is playing in the currency market to support the yen.
Healthcare
PAST TOP PICK
(A Top Pick Aug 06/21, Down 15%) Frustrating stock move movement because it is in healthcare and is the second largest producer of endoscopes and eye glass lenses. However the market is gravitating towards pharmaceutical. Also a smaller part is tied to the tech space which is doing well and could be doing even better when techs improve. He is a long term holder but doesn't know the long term catalysts.
Healthcare